Targets › ODC1
3 programs from 2 companies in 17 trials: 8 Phase 2, 7 Phase 1, 1 Phase 4, 1 Phase 3; Oncology, Metabolic and endocrine, Immunology; next expected readout Feb 2028.
Catalyzes the first and rate-limiting step of polyamine biosynthesis that converts ornithine into putrescine, which is the precursor for the polyamines, spermidine and spermine. Polyamines are essential for cell proliferation and are implicated in cellular processes, ranging from DNA replication to apoptosis. (UniProt, P11926)
Open in Phaseline: the race on ODC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Aminex Therapeutics | AMXT 1501 Dicaprate Ornithine decarboxylase (ODC) inhibitor | ODC1 | Phase 1 | Melanoma (Skin Cancer); Atypical Teratoid/Rhabdoid Tumor | Feb 2028 |
| Aminex Therapeutics | Eflornithine Hydrochloride Ornithine decarboxylase inhibitor | ODC1 | Phase 1 | Melanoma (Skin Cancer); Type 1 Diabetes; Neuroblastoma; Medulloblastoma … | Feb 2028 |
| Orbus Therapeutics | Eflornithine Ornithine decarboxylase inhibitor | ODC1 | Phase 1 | Glioblastoma, IDH-wildtype; Hirsuitism; Colorectal Neoplasms; Prostate Cancer … | – |
Neuroblastoma (3) Melanoma (Skin Cancer) (2) Atypical Teratoid/Rhabdoid Tumor (2) Type 1 Diabetes (1) Medulloblastoma (1) Osteosarcoma Recurrent (1) Glioblastoma, IDH-wildtype (1) Hirsuitism (1) Colorectal Neoplasms (1) Prostate Cancer (1) High Risk Neuroblastoma (1) Osteosarcoma (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.